On June 8, 2020 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), reported that Avi Oler, Senior Vice President, Corporate Development, will present at BIO Digital 2020, being held virtually June 8 – 12, 2020 (Press release, Onconova, JUN 8, 2020, View Source [SID1234560892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Oler will provide an overview of the Company’s corporate development objectives and upcoming milestones for its lead candidate rigosertib and its oncology product candidate pipeline. The presentation will be available here for viewing on-demand.

Mr. Oler will be available for virtual meetings throughout BIO Digital. To arrange a meeting, please visit the BIO One-on-One Partnering webpage.